Company
BioMosaics is a quality provider of reagents, antibodies and immunoassays for detection of human Glypican-3.
We commercialize biomarker assays and reagents for detection of human Glypican-3 (GPC3), for use in various clinical and research settings. We take pride in providing you with products that are reliable, consistent and dependable. Our product and service focus is the CanAg® Glypican-3 EIA (immunoassay for serum/plasma) and primary antibodies for immunohistochemistry/immunocytology.
Leadership
Directors
Ronald D. Guttmann, MD, FRCPC. Dr. Guttmann is Emeritus Professor of Medicine and former Director of the McGill University Centre for Clinical Immunobiology and Transplantation. Dr. Guttmann has been active in the biomedical industry and biotechnology investment consulting since 1985.
Mark Allegretta, PhD. Dr. Allegretta has over 30 years of experience in biotechnology and academic research and development. He received his PhD from the University of Vermont in 1990, and was a post-doctoral fellow at Stanford University School of Medicine. Dr. Allegretta is a BioMosaics co-founder and held postions in Connetics Corporation and InterMune Pharmaceuticals. He was most recently Vice President of Research for the National Multiple Sclerosis Society and currently has transitioned to part-time as Senior Director of Research.
Thomas S. Gillespie, B.C.L. Mr. Gillespie is the former President of Tyringham Investments and prior to 2001 he was a Senior Partner of Ogilvy Renault, a major Canadian law firm, where he was a member of the firm’s Executive Committee for ten years. Mr. Gillespie has served as a director or officer of a number of corporations including Volvo Canada, Guerlin Canada, Imperial Tobacco of Canada, and the Daily Mail and General Trust, England.
Partners
Jorge Filmus PhD - Senior scientist, Biological Sciences, Sunnybrook Research Institute
Professor Filmus received his M.Sc.in clinical biochemistry in 1979 and a PhD in Biological Chemistry from the University of Buenos Aires, Argentina. He is currently Senior Scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute and Professor, Department of Medical Biophysics, University of Toronto. His discovery of the specific expression of Glypican-3 in Hepatocellular Carcinoma led to the development of BioMosaics clinical diagnostic products and his involvement in our research effort is instrumental in understanding the biology of Glypican-3. Dr. Filmus' research activities focus on the diagnosis and treatment of liver cancer, and the role of glypicans in inherited disorders and cancer.
Serge Jothy MD - Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto
Dr. Serge Jothy received his medical degree from the University of Bordeaux, France. He then moved to McGill University in Montreal, where he received a PhD in experimental medicine. Subsequently, he trained in anatomic pathology at Queen's University before returning to McGill and the Royal Victoria Hospital, Montreal, in a staff position. In 1997, having reached the position of Full Professor in the Department of Pathology at McGill, Dr. Jothy was at Sunnybrook Health Sciences Centre as Head, Division of Anatomic Pathology until 2001. He joined the Department of Laboratory Medicine at St. Michael’s Hospital in 2002 where he was the Chief of the department until June 2014. In addition to his leadership and clinical activities, Dr. Jothy is an active scientist in the area of cancer cell biology and has published over 120 peer-reviewed papers. His laboratory is investigating the mechanisms used by cancer cells to invade adjacent normal tissues and produce distant metastases. The investigations focus on how tumour cells become motile by modulating cell adhesion mechanisms. By extension, the studies are also directed at understanding how molecular alterations in critical components of the extracellular matrix contribute to the invasion of tumour cells, and how various compounds can block tumour invasion.